(CERS) Cerus - Overview
Stock: Platelets, Plasma, Red Blood Cells, Cryoprecipitation, Pathogen Inactivation
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 68.7% |
| Relative Tail Risk | -10.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.46 |
| Alpha | -4.95 |
| Character TTM | |
|---|---|
| Beta | 1.618 |
| Beta Downside | 1.493 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.21% |
| CAGR/Max DD | -0.17 |
Description: CERS Cerus December 31, 2025
Cerus Corporation (NASDAQ:CERS) is a biomedical-products firm that commercializes the INTERCEPT Blood System, a proprietary pathogen-reduction technology applied to platelets, plasma, red blood cells, and cryoprecipitate. The system uses a photochemical process to inactivate viruses, bacteria, and parasites in donated blood components, and is sold through a direct sales force and regional distributors across the United States, Europe, the CIS, the Middle East, Latin America, and other international markets. Founded in 1991 and headquartered in Concord, California, Cerus positions itself as a safety-first solution for transfusion medicine.
Key recent metrics (as of FY 2023) include revenue of roughly $115 million, a cash balance of $180 million, and a net loss of $12 million, reflecting ongoing R&D investment and market expansion costs. The global pathogen-reduction market is projected to grow at a 7-8% CAGR through 2030, driven by stricter regulatory requirements and heightened awareness of emerging infectious threats such as Zika and SARS-CoV-2. Competitive pressure comes primarily from alternative pathogen-inactivation platforms (e.g., Amicus, Mirasol), making market share gains contingent on clinical data demonstrating superior efficacy and cost-effectiveness.
For a deeper, data-driven look at CERS’s valuation and risk profile, consider reviewing the analyst tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -16.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 5.59 > 1.0 |
| NWC/Revenue: 39.51% < 20% (prev 48.95%; Δ -9.44% < -1%) |
| CFO/TA 0.02 > 3% & CFO 3.57m > Net Income -16.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (191.8m) vs 12m ago 3.45% < -2% |
| Gross Margin: 55.19% > 18% (prev 0.56%; Δ 5463 % > 0.5%) |
| Asset Turnover: 98.43% > 50% (prev 92.98%; Δ 5.46% > 0%) |
| Interest Coverage Ratio: -0.86 > 6 (EBITDA TTM -5.87m / Interest Expense TTM 8.43m) |
Altman Z'' -15.00
| A: 0.37 (Total Current Assets 167.1m - Total Current Liabilities 88.4m) / Total Assets 215.2m |
| B: -5.01 (Retained Earnings -1.08b / Total Assets 215.2m) |
| C: -0.04 (EBIT TTM -7.24m / Avg Total Assets 202.4m) |
| D: -7.05 (Book Value of Equity -1.08b / Total Liabilities 153.0m) |
| Altman-Z'' Score: -21.59 = D |
Beneish M -3.01
| DSRI: 1.08 (Receivables 29.8m/24.4m, Revenue 199.2m/176.2m) |
| GMI: 1.01 (GM 55.19% / 55.66%) |
| AQI: 0.90 (AQ_t 0.16 / AQ_t-1 0.17) |
| SGI: 1.13 (Revenue 199.2m / 176.2m) |
| TATA: -0.09 (NI -16.0m - CFO 3.57m) / TA 215.2m) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of CERS shares?
Over the past week, the price has changed by -7.76%, over one month by +4.39%, over three months by +47.59% and over the past year by +13.83%.
Is CERS a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CERS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.7 | 118.2% |
| Analysts Target Price | 4.7 | 118.2% |
| ValueRay Target Price | 2.2 | 4.7% |
CERS Fundamental Data Overview February 04, 2026
P/B = 7.2975
Revenue TTM = 199.2m USD
EBIT TTM = -7.24m USD
EBITDA TTM = -5.87m USD
Long Term Debt = 48.7m USD (from longTermDebt, last quarter)
Short Term Debt = 38.9m USD (from shortTermDebt, last quarter)
Debt = 98.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 82.5m USD (from netDebt column, last quarter)
Enterprise Value = 465.3m USD (445.6m + Debt 98.2m - CCE 78.5m)
Interest Coverage Ratio = -0.86 (Ebit TTM -7.24m / Interest Expense TTM 8.43m)
EV/FCF = 1000.0x (Enterprise Value 465.3m / FCF TTM 168.0k)
FCF Yield = 0.04% (FCF TTM 168.0k / Enterprise Value 465.3m)
FCF Margin = 0.08% (FCF TTM 168.0k / Revenue TTM 199.2m)
Net Margin = -8.01% (Net Income TTM -16.0m / Revenue TTM 199.2m)
Gross Margin = 55.19% ((Revenue TTM 199.2m - Cost of Revenue TTM 89.3m) / Revenue TTM)
Gross Margin QoQ = 53.40% (prev 55.25%)
Tobins Q-Ratio = 2.16 (Enterprise Value 465.3m / Total Assets 215.2m)
Interest Expense / Debt = 2.16% (Interest Expense 2.12m / Debt 98.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -5.72m (EBIT -7.24m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.89 (Total Current Assets 167.1m / Total Current Liabilities 88.4m)
Debt / Equity = 1.60 (Debt 98.2m / totalStockholderEquity, last quarter 61.5m)
Debt / EBITDA = -14.05 (negative EBITDA) (Net Debt 82.5m / EBITDA -5.87m)
Debt / FCF = 491.2 (Net Debt 82.5m / FCF TTM 168.0k)
Total Stockholder Equity = 57.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.89% (Net Income -16.0m / Total Assets 215.2m)
RoE = -27.94% (Net Income TTM -16.0m / Total Stockholder Equity 57.1m)
RoCE = -6.84% (EBIT -7.24m / Capital Employed (Equity 57.1m + L.T.Debt 48.7m))
RoIC = -4.03% (negative operating profit) (NOPAT -5.72m / Invested Capital 141.9m)
WACC = 10.04% (E(445.6m)/V(543.8m) * Re(11.88%) + D(98.2m)/V(543.8m) * Rd(2.16%) * (1-Tc(0.21)))
Discount Rate = 11.88% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.89%
[DCF Debug] Terminal Value 62.06% ; FCFF base≈168.0k ; Y1≈112.2k ; Y5≈53.0k
Fair Price DCF = N/A (negative equity: EV 762.4k - Net Debt 82.5m = -81.8m; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-38.74%), DCF may be unreliable
EPS Correlation: 76.28 | EPS CAGR: 44.52% | SUE: 0.68 | # QB: 0
Revenue Correlation: 67.86 | Revenue CAGR: 7.73% | SUE: -0.54 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.03 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.03 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+68.8% | Growth Revenue=+9.3%